RxDoctor Payments Data

Rene Fernandez, MD

Internal Medicine · Key Largo, FLNPI 1760658520

Payments from drug & device makers

$556in general payments, 2019–2025

Across 20 payments — averaging $27.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$108
  • Novartis$75
  • Welch Allyn$66
  • Braemar Manufacturing, LLC$58
  • Exact Sciences$58
  • Novo Nordisk$41
  • plus $149 from 6 others

What the payments were for

  • Food & beverage$49088%
  • Other$6612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$108
Novartis3$75
Welch Allyn1$66
Braemar Manufacturing, LLC1$58
Exact Sciences2$58
Novo Nordisk2$41
Lilly USA, LLC2$33
Hologic Sales And Service, LLC1$30
Tempus AI, Inc1$29
Amgen1$27
Watermark Medical, Inc.1$17
Pfizer1$13

How this compares

$556 in reported general payments places this provider in the 55th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$338,321
Medicare patients
600
Services billed
6,725

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban28$25,496
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$16,206
OzempicSemaglutide11$14,809
MyrbetriqMirabegron15$9,435
ArexvyRsvpref3 Antigen/As01e/Pf25$7,559
Rosuvastatin Calcium57$1,037
Pantoprazole Sodium36$1,004
Losartan Potassium60$930
Atorvastatin Calcium44$745
Ezetimibe18$733
Levothyroxine Sodium36$718
Tamsulosin Hcl27$607
Famotidine32$569
Azelastine Hcl20$540
Simvastatin23$425

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$25,49628 claims
GSKTrelegy Ellipta, Arexvy$108$23,76542 claims
Novo NordiskOzempic$41$14,80911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Key Largo

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →